~
This is very good news for medical marijuan, according to a policy statement released Monday.
 
"The AAP strongly supports research and development of pharmaceutical cannabinoids and supports a review of policies promoting research on the medical use of these compounds," the AAP statement reads. To that end, the group recommends that the DEA reschedule marijuana from a Schedule I controlled substance to Schedule II.
 
Under the Controlled Substances Act, the U.S. has five "schedules" for drugs and chemicals that can be used to make drugs. Schedule I is reserved for drugs that the DEA considers to have the highest potential for abuse and no "currently accepted medical use." Marijuana has been classified as Schedule I for decades, along with other substances like heroin and LSD. While a lower schedule for marijuana would not make it legal, it could ease restrictions on researching the drug.
 
While the AAP added that it does not support the legalization of marijuana, citing the potential harms to children and adolescents, it did say that it "strongly" supports the decriminalization of marijuana use and encourages pediatricians to "advocate for laws that prevent harsh criminal penalties for possession or use of marijuana."
 
"A focus on treatment for adolescents with marijuana use problems should be encouraged, and adolescents with marijuana use problems should be referred to treatment," the statement said.
 
Monday's statement is the first change to AAP policy on the issue since 2004. At that time, the group did not request a schedule change.
 
The DEA is the federal agency that is primarily responsible for regulating controlled substances like marijuana. But the Food and Drug Administration, along with the National Institute on Drug Abuse, provides the DEA with recommendations about the appropriate level of restriction for various illicit substances.
 
The FDA is already engaged in a review of the medical evidence surrounding the safety and effectiveness of marijuana. The evaluation was initiated due to a request from the DEA, following a number of citizens' petitions asking for a review. According to the Controlled Substances Act, the government must consider eight factors when deciding the schedule under which a substance should be classified. These include its potential for abuse, the state of current scientific knowledge about the substance and its psychic or physiological dependence liability.
 
The FDA could not confirm to The Huffington Post how long the review process takes, but expressed support for AAP's move.
 
"FDA can’t comment on the suggestion to change the schedule for marijuana, as the latest FDA review of the issue -- known as the 8-factor analysis -- is currently ongoing, FDA press officer Jeff Ventura said Monday. "However, FDA agrees with the call by the AAP for rigorous scientific research into the uses of marijuana ... [and] supports those in the medical research community who seek to study marijuana."
 
The DEA has made previous requests, in 2001 and 2006, to the FDA for an evaluation of marijuana. Those requests were the results of public petitions requesting a rescheduling, FDA Deputy Director Doug Throckmorton explained in testimony delivered during a congressional hearing last year. But DEA regulators determined after both of those reviews that marijuana should remain a Schedule I substance. The FDA cited insufficient available research about marijuana's effectiveness in treating a number of ailments.
 
While the FDA hasn't advocated for legalization of the drug, it said in a 2014 update to its guidelines on marijuana that it is "aware that there is considerable interest in its use to attempt to treat a number of medical conditions, including, for example, glaucoma, AIDS wasting syndrome, neuropathic pain, cancer, multiple sclerosis, chemotherapy-induced nausea, and certain seizure disorders."
 
Matt Ferner ~ January 27, 2015
 
 
August 16, 2019

Poll Finds 63% of Americans Support Cannabis…

According to a poll from Investor’s Business Daily and TIPP, 63 percent of Americans support cannabis legalization, including 75 percent…
August 16, 2019

How Essential Oils Enhance Marijuana's Entourage Effect…

When cannabis oil is mixed with essential oils from other plants, the presence of new terpenes can also make a…
August 16, 2019

Scientific Study: This Marijuana Flavor Might Fight…

“The findings demonstrate the potential for this new cannabis derivative in the treatment of both localized and advanced pancreatic cancer,”…
August 16, 2019

Up In Smoke: Pre-Employment Marijuana Testing Goes…

Starting next year, job seekers in New York City and Nevada will no longer have to worry about whether they’ll…
August 15, 2019

Report: California Cannabis Market on Track to…

After briefly faltering a year ago, California’s massive cannabis industry seems to be regaining steam.
August 15, 2019

Time to get acquainted with the industrial…

Used in Europe for more than 3,200 years, hemp today represents an annual market opportunity of $1 bn (~€692m) for…
August 15, 2019

How Does Your State Rate for Medical…

Americans for Safe Access (ASA) aims the report at lawmakers each year, prodding them to make progress relative to their…
August 15, 2019

UC Davis Partners With DEA-Approved Company to…

Researchers at the University of California, Davis, have partnered with a federally compliant pharmaceutical company to analyze the chemical and…
August 14, 2019

When It Comes to Sustainability, Hemp Is…

The crop’s legalization could change the industry — and threaten cotton’s dominance.
August 14, 2019

Here’s How Cannabinoids Quell Anxiety - Cannabis…

Cannabis has powerful anxiolytic (anti-anxiety) properties, and when administered as-needed, can provide relief from several anxiety disorders.
August 14, 2019

Auburn, Maine made a map to help…

With new state rules on how to grow, sell and buy recreational marijuana poised to take effect in September and…